Airway inflammation and structural changes in airway hyper-responsiveness and asthma: An overview

Louis-Philippe Boulet MD FRCPC, Jamila Chakir PhD, Jean Dubé MSc, Catherine Laprise MSc, Michel Boutet MD FRCPC, Michel Laviolette MD FRCPC
Unité de Recherche, Centre de Pneumologie de l’Hôpital Laval, Réseau canadien des Centres d’excellence en santé respiratoire, Sainte-Foy, Québec

Asthma treatment has moved from bronchodilator therapy to an emphasis on anti-inflammatory therapy. Airway inflammation is believed to induce airway hyper-responsiveness (AHR) through the release of mediators that increase the airway response to agonists. However, the exact contribution of airway inflammation in the physiology of airway hyper-responsiveness remains undefined. Structural modifications in airways resulting from inflammation may contribute to the development and persistence of AHR and the development of asthma. This paper reviews some of the main components of airway inflammation and structural changes in asthma, and discusses how these processes may interact to modify airway function and induce respiratory symptoms.

Key Words: Airway inflammation, Airway remodelling, Asthma, Cytokines, Fibroblast, Subepithelial fibrosis

Une vue d’ensemble de l’inflammation des voies aériennes et des changements structuraux dans l’hyperréactivité des voies aériennes et dans l’asthme


Correspondence and reprints: Dr Louis-Philippe Boulet, Hôpital Laval, 2725 Chemin Sainte-Foy, Sainte-Foy, Québec G1V 4G5.
Telephone 418-656-4747, fax 418-656-4762, e-mail lpboulet@med.ulaval.ca

Can Respir J Vol 5 No 1 January/February 1998
tory insult per se, to the development and the persistence of AHR and influence the development of symptomatic asthma (Figures 1,2) (8-10). The relevance of these various changes and their contribution to the development of abnormal airway function, however, is still obscure. In this report and more extensively in the other papers included in this issue of the Canadian Respiratory Journal, some of the main components of airway inflammation and structural changes in asthma are reviewed, and how these two processes may interact to modify airway function and induce respiratory symptoms are discussed.

**AIRWAY INFLAMMATION AND ASTHMA**

Analysis of bronchoalveolar lavage (BAL) cells and bronchial biopsies obtained from asthmatic patients has made it possible to investigate the role of inflammatory and structural changes in the development of AHR and symptomatic asthma (4,5,8,11-12). In sensitized asthmatic subjects, allergen exposure increases both BAL eosinophil and epithelial cell counts (13,14). Microscopy studies of asthmatic airways have shown, even in mild asthma, a cellular infiltrate, mainly of activated lymphocytes and eosinophils, subepithelial collagen deposition, bronchial epithelium disruption, alterations in cilia, subepithelial edema, mucus cell hyperplasia and smooth muscle structural changes (8,12,15). Both natural and laboratory allergen exposures increase the inflammatory features observed in bronchial biopsies (15,16).

These observations support the concept that asthma is an inflammatory disease. However, although a relationship has been found between the airway inflammatory process and AHR, this is not always clinically evident (4,5-7,17,18). Asthma and AHR may persist with only minimal evidence of inflammation (19); however, persistence of a certain degree of airway inflammation despite the regular use of a clinically adequate dose of inhaled corticosteroids has been reported (20).

**CELLS AND CYTOKINES: THE WORLD OF INFLAMMATION**

The acceptance of asthma as an inflammatory disease has not only modified its treatment, but also stimulated research to understand the particular features of asthmatic inflammation. As with other inflammatory responses, many cell types and mediators are involved. The cellular and humoral components of the asthmatic inflammatory response have been previously reviewed (3,21,22) and are discussed in other papers in the symposium; therefore, only a few aspects are discussed.

The cascade of events following allergen exposure, starting with host sensitization (at least in allergic asthma) and airway inflammation, and leading to AHR and asthma symptoms remains to be defined. Although asthma is probably not a ‘one cell’ or ‘one mediator’ disease, the associated inflammatory process is characterized by certain predominant features: mast cell activation; lymphocyte and eosinophil activation and recruitment; increased vascular permeability; and epithelial desquamation (4,23-25). Furthermore, a variety of structural alterations have been reported, including goblet cell hypertrophy, smooth muscle hypertrophy or hyperplasia and extracellular matrix modifications, including subepithelial fibrosis (8,10,12). These inflammatory and structural changes probably result from complex positively or negatively orchestrated mechanisms in tissues, including structural cell-immune cell communications via cell-cell contacts, mediator- and cytokine-driven messages and cell-extracellular matrix interactions (26-29).

---

**Figure 1** Potential pathways by which inflammation and remodeling can contribute to the development of airway hyperresponsiveness. *Reversible; **Less reversible

**Figure 2** Hypothetical evolution of inflammatory or structural airway changes over time in different types of asthma. RADS Reactive airways dysfunction syndrome
PLASMA TRANSDUSSION AND AIRWAY WALL THICKNESS

Plasma transudation may contribute to the increased airway response (25,30). The observation that left ventricular failure and increased pulmonary vascular volume can be associated with an increase in airway responsiveness supports a role for bronchial edema and increased airway fluid content as modulators of airway responsiveness (31,32). An excellent review describes the role of increased airway microvascular permeability in airway inflammation and obstruction (25). The influence of increased airway water content may be only transient, as in heart failure. It is conceivable that airway bloodflow and vascular permeability are increased in asthma as in other inflammatory diseases, and that they can lead to an increased vascular turgidity and plasma transudation in response to chronic and acute inflammation. A model developed by Hogg and coworkers (33) suggests that airway wall thickness can be an important factor in the pathogenesis of AHR and that even a minimal reduction of airway calibre, due to airway submucosal edema, may increase the response to agonists.

AIRWAY STRUCTURE CHANGES IN ASTHMA

Airways are lined by a pseudostratified, ciliated epithelium with a few goblet cells. In normal subjects there are very few inflammatory cells in the submucosa and the basement membrane is thin (usually 5 to 7 µm), composed of laminin and type IV collagen.

In a comparative analysis of bronchial biopsies obtained from subjects with allergic or occupational asthma, chronic cough or allergic rhinitis, and normal controls, one of the main histological differences found between asthmatic and nonasthmatic subjects was the presence of a linear subepithelial collagen deposition beneath the basement membrane in asthmatic subjects (34). In subjects with rhinitis, a similar collagen deposition was observed, but it was focal and less than that seen in asthmatics. In a global analysis of bronchial biopsy features of the different groups of subjects, the degree of subepithelial fibrosis showed a correlation with AHR to methacholine (34).

The possibility that collagen deposition beneath the layer of smooth muscle may enhance the contractility of the airways is in keeping with the model of Wiggs et al (35). It is possible that the same degree of smooth muscle constriction in an airway wall thickened by collagen deposition beneath the basement membrane or by edema could result in an enhanced airway response to bronchoconstrictor stimuli compared with normal airways, although it is possible that this collagen deposition limits maximal bronchoconstriction. Another mechanism by which airway function may be modified following such changes is the increase in tensile stiffness and resistance to deformation of the airways, explaining the reduction in distensibility described in asthmatic airways (36). This may also prevent full expansion of airways from deep inspiration during bronchial provocation tests, possibly explaining the lack of response to stretch in asthmatic subjects (and reproduced in normal subjects breathing at low lung volumes) noted by Skloot et al (37) and acting to antagonize the bronchodilating effect of a deep inspiration (38).

In this regard, the role of changes in surface tension of the airways remains to be studied. Inflammation can alter the integrity of airway epithelium and its surfactant properties, potentially increasing surface tension and making airway opening more difficult compared with the force needed to close them (39).

Increases in airway wall thickness may also be due to hyperplasia and/or hypertrophy of airway smooth muscle (40). Although implicated in the development of AHR, hyperplasia or hypertrophy of smooth muscle is not always present in asthmatics who die of other causes than asthma (41). Furthermore, a recent study published by Thomson et al (42) provided no evidence of increased airway smooth muscle in the large airways of asthmatic subjects, suggesting that differences in the mechanical responses of asthmatic airways could not be solely explained by the amount of smooth muscle. On the other hand, Lambert et al (43) showed that asthmatic airways have fewer intraluminal mucosal folds than constricted normal airways, and that this may lead to greater airway narrowing. Thus, not only may the airway wall thickness influence airway response, but also its responses to contraction, including folding of the submucosa.

Other factors, such as the reduction of lung-airway interdependence because of adventitial edema or increased elastin degradation induced by the inflammatory process, may also increase airway contractility (44). Finally, little is known about the contribution of changes in other airway structures such as cartilage and vessels to changes in airway function.

ORIGIN OF THE AIRWAY SUBEPITHELIAL FIBROSIS

In asthma, the subepithelial collagen is composed of types III and V collagens and fibronectin (8,44,45). This deposition has been attributed to myofibroblasts (46); the number of myofibroblasts in the subepithelial area of the airways correlates with basement membrane thickness (47). Myofibroblasts are likely to be one of the important cells involved in the changed contractile properties of the airways, following inflammatory insults. Myofibroblasts were initially found on electron micrographs of contracting experimental granulation tissue (48). During normal wound healing, they may temporarily acquire a smooth muscle phenotype in response to an increased contractile functional demand (49,50). When this functional effect is no longer needed, myofibroblasts appear to be replaced by fibroblasts, probably during a dedifferentiation process, with the cell losing its contractile properties.

RELATIONSHIPS BETWEEN INFLAMMATION AND AIRWAY FIBROSIS

The airway repair process observed in asthma may be initiated or modulated by mediators and cytokines released by lymphocytes, eosinophils, macrophages and mast cells, all of which are increased in asthmatic subjects. Structural cells
can respond to this chronic inflammatory process by present-
ing an altered phenotype that may contribute to the chro-
nocity of inflammation (Figure 3). Lymphocytes produce
cytokines such as interleukin (IL)-5, IL-3 and granulocyte
colony stimulating factor (GM-CSF), which are involved in
eosinophil differentiation, maturation and survival
(26,51,52). The eosinophil may then accentuate the repair
process by continuing damage to the epithelium. Epithelial
cells may also be involved in the fibrotic process because
they are able to release different mediators and cytokines
such as GM-CSF, tumour necrosis factor (TNF) and IL-8
(53). Fibroblasts can be recruited through the influence of
monocyte-derived cytokines IL-1 and TNF (54). Activated
macrophages and eosinophils also produce tumour growth
factor-beta1 (TGF-β1), which has been shown to allow trans-
formation of fibroblasts into myofibroblasts with actin ex-
pression. Desmoulière et al (55) showed that TGF-β1 plays
an important role in myofibroblast differentiation during
wound healing and fibrocontractive diseases. After GM-CSF
administration, cluster-like accumulations of macrophages
play a role in stimulating alpha-smooth muscle actin expres-
sion in myofibroblasts (56).

Myofibroblasts are located in the collagen layer (44,47);
electron microscopic analysis of these cells showed myofi-
broblasts with elongated nucleus, peripheral condensation of
chromatin and presence of microfilament bundles, indicating
a contractile capacity. These fibroblastic cells were isolated
from asthmatic and normal bronchial. A portion of these cells
express alpha-actin in accord with the in vivo findings. Be-
cause these cells express microfilament bundles, the authors
tested their capacity to generate contractile forces in com-
parison with normal bronchial fibroblasts (57). Fibroblasts
were mixed with soluble type I collagen. The medium sup-
plemented with serum and contraction was measured by se-
rial area measurements; a higher contractile capacity was
found in asthmatic bronchial fibroblasts than in normal cells.
This increased contractility was correlated with airway re-
sponsiveness to methacholine for day 1 and day 2.

The importance of these bronchial fibroblasts in the in-
flammation process remains to be determined. Fibroblasts
from different inflammatory sites have a large repertoire of
cytokines that mediate immune-mesenchymal interactions.
Furthermore, growth factors are probably involved in the fi-
broblastic proliferation (58). Gauldie et al (27) reported that
there may be a persistent phenotypic change of fibroblasts in
chronic inflammation and suggested that these altered cells
may contribute to the maintenance of the inflammatory pro-
cess. However, up to now, there is no evidence that such a
phenomenon is involved in asthma.

AIRWAY EPITHELIAL ALTERATIONS AND AHR

Epithelial damage is considered one of the main features
of asthma (59). Airway responsiveness correlates with the
extent of epithelial desquamation in subjects with AHR, al-
though this correlation is rather weak (12,34). The cause of
epithelial shedding is unknown, but it may be related to un-
derlying edema. Beneath the bronchial epithelium, there is a
rich network of microvessels. Separation of epithelial cells
can occur following compression by the increased fluid vol-
ume present in the submucosa due to the inflammatory-
induced exudation. In this regard, Montefort et al (60)
showed that shedding of epithelial cells occurs along a supra-
basal plane of cleavage between suprabasal and basal cell
layers, which might be more vulnerable to insults. Underly-
ing airway edema may facilitate this phenomenon due to a
physical effect on the attachment of basal and suprabasal
cells. Epithelial desquamation is probably enhanced by the
effect of toxic substances, such as basic proteins and oxygen
radicals, released by eosinophils or other cells (61).

Figure 3) Interactions between airway epithelium and inflamma-
tory cells through the influence of cytokines. GM-CSF Granulocyte
colony stimulating factor; IL Interleukin; TNF α Tumour necrosis
factor-alpha

EFFECTS OF THERAPY ON AIRWAY
INFLAMMATION AND STRUCTURAL CHANGES

Anti-inflammatory agents such as corticosteroids reduce
airway inflammation, as shown by a decrease in the numbers
of airway eosinophils, mast cells and activated lymphocytes
and, in most subject, provision of a significant but often par-
tial resolution of airway responsiveness (7,62,63).

Corticosteroids may help to restore epithelial integrity but
generally they do not induce asthma remission (64). Further-
more, they are less effective in reducing sub-basement mem-
brane collagen deposition, suggesting that once this process
has been underway for months or years, it will not reverse
with treatment (65). Improvement in airway responsiveness
with corticosteroids may be associated with a reduction of
airway wall inflammation, but the persistence of an irreversi-
ble AHR may be explained by the fixed structural changes
such as airway wall fibrosis. The study by Lundgren (19) is in
keeping with this possibility, showing that asthmatic subjects
who used inhaled corticosteroids for many years had mini-
mal inflammation but still had AHR and persistent abnormal
collagen deposition beneath the basement membrane.

It is possible that airway structural changes can be reversi-
ble at an early stage of the disease, particularly if treated with potent anti-inflammatory agents such as corticosteroids, but they may become irreversible when the insult persists or is initially severe as seen in the reactive airways dysfunction syndrome (RADS) (66). Irreversible airway structural changes and thickening could lead to persistent airflow obstruction and AHR, as observed in some patients with long-standing asthma without significant smoking history (67).

CONCLUSIONS

We reviewed some possible mechanisms by which the asthma inflammatory process may lead to persistent AHR and symptomatic asthma, particularly through its influence on airway structure. Asthma is probably due to the effects of environmental stimuli which induce airway inflammation and secondary bronchial structural changes in a genetically predisposed individual. Atopy certainly contributes to such a phenomenon in many individuals, but chemical (industrial) toxic agents or viral infections may also be involved in others. The asthmatic airway inflammatory response can be considered as a defense mechanism, protecting the individual against an exogenous aggression (eg, an allergen), or possibly as an autoimmune response secondary to a latent viral infection or other etiology. If the inflammatory process does not induce any morphological change in the airways, its only manifestation may be a cough via cough receptor stimulation by mediators. If it persists because of repeated or continuous stimulus exposure or persistent alteration of inflammatory cell functions, or if the initial stimulus is severe (as in RADS), abnormal repair processes with subepithelial fibrosis will develop, possibly increasing airway contractile properties and leading to the appearance of AHR (Figure 2). Accentuated airway inflammation, particularly airway wall edema, intraluminal secretions and stimulation of neural pathways and changes in airway surface tension, may modulate this increased airway responsiveness. These aspects of inflammation may account for reversible AHR; the addition of structural changes, such as subepithelial airway collagen deposition, may explain an ‘irreversible’ component. With time, particularly if the remodelling continues, the irreversible component of AHR increases. This hypothesis may explain why individuals can have airway hyper-responsiveness without asthma symptoms (68). It also suggests that early treatment of airway inflammation, perhaps even before asthma symptoms appear, might prevent its symptomatic stage.

Finally, we should not forget that other aspects of airway responses such as the maximal bronchoconstrictor response observed in asthma could also be related to structural or inflammatory airway changes; this topic needs to be explored further. Maximal bronchoconstriction is not always proportional to the degree of AHR, and its mechanisms can be different from those leading to AHR. Of particular interest is the hypothesis of a decreased airway elastance as an explanation for this phenomenon (69).

A significant amount of work remains to be done to determine the contribution of the different inflammatory and structural elements to the physiological and clinical changes in asthma.

REFERENCES


